It's the billion dollar question I guess, but with the...

It's the billion dollar question I guess, but with the International Hyperhidrosis Society emailing 50,000 members to let them know there's a brand new product in town that performs exceptionally better than Qbrexza, and with the Telehealth and marketing campaigns we can expect from BOT, along with the salespeople hitting the majority of dermatology offices across the states spruiking this best-in-class new product, I really think you're going to see substantial take-up in the first 6 months!

Conservatively - if BOT attract only 1% of the reported 3.7m sufferers in a derma office looking for a solution (most likely wanting something better than Qbrexza or botox) then you're talking 37,000 patients. 37k patients @$700 a script x 12 months = $300m. Halve that and clearly its $150m.

Sofdra is way superior to Qbrexza, so I think it's hard to look at it as though it's just going to perform the same. New product, new excitement, new marketing initiatives, new exposures to PAH sufferers. Not up-ramping - just saying it looks completely doable.